| 产品详情 |
| Edit |   |
|---|
| Product Name | ORY-1001 |
|---|
| Description | Purity >98%. Lysine-specific demethylase 1 (LSD1) demethylates H3K4 and H3K9, resulting in transcriptional repression. It also controls the tumor suppressor activity of p53 by demethylating a specific p53 lysine residue (LYS370 ). ORY-1001 is an orally available, selective inhibitor of LSD1 (IC50 < 20 nM). It targets acute myeloid leukemia (AML) stem cells and significantly reduces tumor cell load while increasing survival time in mouse models of AML. ORY-1001 is in clinical trials for cancer treatment. |
|---|
| Size | n/a |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | rel- N1 -[(1R,2S)-2-phenylcyclopropyl]-1,4-cyclohexanediamine, dihydrochloride, RG-6016 |
|---|
| Gene, Accession, CAS # | CAS: 1431326-61-2 |
|---|
| Catalog # | LS-H9207 |
|---|
| Price | |
|---|
| Order / More Info | ORY-1001 from LIFESPAN BIOSCIENCES INC. |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|